ÂÜÀòÂÒÂ×

Larry is CEO at Health2047 Inc. An experienced biotechnology leader, he thrives in the development of drugs and platforms to treat illnesses. Prior to joining Health2047 Inc., Larry served as Executive Vice President of Research and Business Development at Kadmon Holdings, a publicly-traded biotechnology company focused on developing therapies for immune and fibrotic diseases. His previous experiences include serving as President and CEO of San Francisco’s VIA Pharmaceuticals, where he spearheaded efforts to develop small-molecule drugs to treat cardiovascular diseases; President and CEO of Fremont-based proteomics company Zyomyx; COO of Menlo Park-based Progenitor, Inc., which developed therapies for respiratory disease and oncology; and Vice President of Research of Somatix Therapy Corporation, a pioneer in gene therapy. He earned a PhD degree in Microbiology from the University of Illinois, and completed his postdoctoral work in Molecular Biology at the Dana-Farber Cancer Institute and the Department of Biochemistry at Harvard Medical School. He earned his B.A. from Grinnell College.